nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

2015659 citationsJournal Articlebronze Open Access

Authors

David Goldstein · Hospital Clínico San Carlos

Robert H. El-Maraghi · Hospital Clínico San Carlos

Pascal Hammel · Hospital Clínico San Carlos

Volker Heinemann · Hospital Clínico San Carlos

Volker Kunzmann · Hospital Clínico San Carlos

Javier Sastre · Hospital Clínico San Carlos

Werner Scheithauer

Abstract

These data confirm and extend the primary report of OS, supporting the superior efficacy of nab-paclitaxel plus gemcitabine over gemcitabine alone. Subgroup analyses support the relevance of CA 19-9 and NLR as prognostic markers in metastatic pancreatic cancer.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 107, Issue 2, pp. dju413-dju413

DOI: 10.1093/jnci/dju413

Field-Weighted Citation Impact: 38.22